Results 261 to 270 of about 564,426 (377)

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma

New England Journal of Medicine, 2017
J. Connors, W. Jurczak, D. Straus, S. Ansell, W. Kim, A. Gallamini, A. Younes, Sergey M. Alekseev, Á. Illés, M. Picardi, E. Lech-Maranda, Y. Oki, T. Feldman, P. Smolewski, K. Savage, N. Bartlett, J. Walewski, Robert Chen, R. Ramchandren, P. Zinzani, D. Cunningham, A. Rosta, N. Josephson, Eric Song, J. Sachs, Rachael Liu, H. Jolin, D. Huebner, J. Radford   +28 more
semanticscholar   +1 more source

Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions

Clinical Endocrinology, EarlyView.
ABSTRACT Objective To provide clinicians involved in managing menopause with a summary of current evidence surrounding menopause hormone therapy (MHT). Design The authors evaluate and synthesize existing pooled evidence relating to MHT's clinical indications, efficacy, and safety and explore the limitations of existing data. Patients The review focuses
Annice Mukherjee, Susan R. Davis
wiley   +1 more source

Optimizing therapy for relapsed/refractory classic Hodgkin lymphoma in the era of PD-1 blockade. [PDF]

Hemasphere
Kuczmarski TM, Lynch RC.
europepmc   +1 more source

Localized non-Hodgkin lymphoma involving the thyroid gland [PDF]

, 2001
Chul S. Ha, Kathleen M. Shadle, L. Jeffrey Medeiros, Richard B. Wilder, Mark A. Hess, Fernando Cabanillas, James D. Cox   +6 more
openalex   +1 more source

Endocrine Implications of Thyroid Incidentalomas Detected During Lymphoma Staging With 18F‐Fluorodeoxyglucose Positron Emission Tomography

Clinical Endocrinology, EarlyView.
ABSTRACT Objective This study investigated the prevalence, characteristics, and endocrine implications of thyroid incidentalomas detected during lymphoma staging using FDG‐PET/CT. Design Retrospective cohort study. Patients A total of 795 adult patients with lymphoma who underwent FDG‐PET/CT for staging at a tertiary oncology centre were included ...
Marcos Tadashi Kakitani Toyoshima, Roberta Morgado Ferreira Zuppani, Isabelle Pinheiro Amaro, Camila Regina Pereira Batista de Macedo, Ricardo Miguel Costa de Freitas, Rodrigo Dolphini Velasques, Juliana Pereira, Rafael Loch Batista, Debora Lúcia Seguro Danilovic, Delmar Muniz Lourenço Jr., Ana O. Hoff   +10 more
wiley   +1 more source

Macrophage Activation Syndrome Revealing Hodgkin Lymphoma: A Pediatric Case Report. [PDF]

Cureus
Hared Bouh A, Moussa Sougueh O, Miqdadi A, Al Ammari I, Dini N.   +4 more
europepmc   +1 more source

Second malignancy after treatment of childhood non-Hodgkin lymphoma [PDF]

, 2001
Wing Leung, John T. Sandlund, Melissa M. Hudson, Yinmei Zhou, Michael L. Hancock, Yunping Zhu, Raul C. Ribeiro, Jeffrey E. Rubnitz, Larry E. Kun, Bassem I. Razzouk, William E. Evans, Ching‐Hon Pui   +11 more
openalex   +1 more source

Efficacy and Safety of Bendamustine‐Rituximab for Nodular Lymphocyte Predominant Hodgkin Lymphoma

European Journal of Haematology, EarlyView.
ABSTRACT Introduction Bendamustine‐rituximab (BR) has demonstrated efficacy and tolerability in the treatment of various indolent B‐cell lymphomas, but there is limited data regarding its outcomes in nodular lymphocyte predominant B‐cell (Hodgkin) lymphoma (NLPBL).
Alexander Robin, Carolyn Owen, Sarah Perry, Lesley Street, Neil Chua, Douglas Stewart, Robert Puckrin   +6 more
wiley   +1 more source

Is GATA3 Useful for Differentiating between Classical Hodgkin Lymphoma and Nodular Lymphocyte-Predominant Hodgkin lymphoma? A Two-Center Study in Tehran, Iran during 2016 to 2022. [PDF]

Asian Pac J Cancer Prev
Rahnavard A, Kosari F, Nili F, Sefidbakht S, Ameli F.   +4 more
europepmc   +1 more source

Non-Hodgkin lymphoma in Uganda: a case–control study

, 2000
Donald Maxwell Parkin, H. Garcia-Giannoli, Martine Raphaël, Antoine Martin, Edward Katangole-Mbidde, Henry Wabinga, John L. Ziegler   +6 more
openalex   +1 more source